Latest research on Betaseron

Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD

Betaseron indications

The interferons were injected second daily (Betaferon or Betaseron), thrice weekly (Rebif), or weekly (Avonex), whereas glatiramer acetate (Copaxone) was initially shown to be effective with daily administration. [source, 2015]
As well as the injectable therapies that have a long history of use as first-line treatments (Betaseron, Rebif, Avonex, Copaxone, Extavia––‘BRACE’), several intravenous or oral therapy options have become available in recent years: natalizumab (Tysabri®; Biogen Idec, initially 2004, then 2006 following temporary withdrawal for safety review); alemtuzumab [Lemtrada®; Sanofi, 2013––European Union (EU) only]; fingolimod (Gilenya®; Novartis, 2010––different indications in the USA and the EU); teriflunomide (Aubagio®; Sanofi, 2012), and dimethyl fumarate (DMF; Tecfidera®; Biogen Idec, 2013) [14]. [source, 2014]
The Betaseron Pregnancy Registry's findings are consistent with these previous reports and reinforce the hypothesis that there are no obvious postnatal effects from in utero interferon β-1b exposure. [source, 2014]
Currently available disease modifying therapies for MS aim to reduce the immune response by targeting immunological pathways: β-interferons, IFNβ-1α (Avonex, Rebif) and IFNβ-1β (Betaseron); the synthetic peptide glatiramer acetate (Copaxone); the antineoplastic agent Mitoxantrone (Novantrone), and; a very late antigen-4 (VLA-4) blocker natulizumab (Tysabri) [7], but all are only partially effective. [source, 2013]
Interferon beta-1b (Betaseron) was the first clinically effective therapeutic agent proven to modify the disease course in MS patients and is thought to exert its therapeutic effects by downregulating expression of MHC II molecules and inhibiting the passage of immune cells into the CNS [3–6]. [source, 2012]
More recently, in the BECOME (Betaseron vs. Copaxone in MS with Triple-Dose Gadolinium and 3-T MRI Endpoints) study, the effect of IFN-β-1b and GA on new active lesions was tested on the 3 T optimized protocol (3 T MRI scanner, a triple dose of Gd, with a 20-min scanning time delay after Gd injection) in 75 patients with relapsing-remitting (RR) MS who underwent serial monthly MRI scans over 12 months [20]. [source, 2012]